| INTRODUC TI ON
Cervical cancer (CC) is the fourth leading cause of cancer death for women and the third most common malignancy in women worldwide, resulting in approximately 300 000 mortalities each year. [1] [2] [3] In 2015, according to Chinese cancer statistics, there were approximately 100 000 new cervical cancer cases and 30 000 mortalities as a result of cervical cancer. 4 In recent years, periodic cancer screening and prompt surgical treatment have increased; however, CC remains a public health concern worldwide because of the indistinct molecular mechanisms of its development and progression.
Long noncoding RNAs (lncRNAs) are nonprotein-coding RNA transcripts that exert a key role in many cellular processes and have potential toward addressing disease etiology. [5] [6] [7] Long noncoding RNA-DANCR is a valuable cancer-related lncRNA whose dysregulated expression was found in a variety of malignancies, including bladder cancer, hepatocellular carcinoma, breast cancer, glioma, colorectal cancer, gastric cancer, osteosarcoma and lung cancer. 8 For example, DANCR played a critical regulatory role in bladder cancer cells and DANCR might serve as a potential diagnostic biomarker and therapeutic target of bladder cancer. 9 In addition, silencing DANCR was shown to efficiently impair colon tumor growth by promoting caspase 3 expression and tumor apoptosis. 10 Importantly, MYC-targeted DANCR promotes cancer, in part, by reducing p21 levels.
11
MicroRNAs (miRNAs) are small noncoding RNAs of 18-22 nucleotides (nt) in length that are able to bind to the 3′-UTR of specific mRNA targets to regulate their translation at the post-transcriptional level. [12] [13] [14] Several previous studies have demonstrated that some miRNAs are dysregulated in many cancers, especially in CC. [15] [16] [17] For example, miR-374b inhibited cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM-2 in cervical cancer. 18 In addition, miR-136 inhibited proliferation and promoted apoptosis and radiosensitivity of cervical carcinoma through the nuclear factor kappa B (NF-κB) pathway by targeting E2F1. 19 Furthermore, miR-346 functioned as a prosurvival factor under endoplasmic reticulum (ER) stress by activating mitophagy in CC cells. 20 However, the level and role of miR-665 in CC remains unclear.
In the present study, using deep-sequencing, The Cancer
Genome Atlas (TCGA) and the OncomiR database, we found that miR-665 was downregulated in CC. 
| MATERIAL SANDME THODS

| Humantissuesamplecollection
Thirty-three pairs (three random pairs for deep-sequencing; 30 pairs for RT-qPCR assay) of human cervical tissue, consisting of human CC and matched normal cervical tissue from the same patient, were G3′; TGFBR1-qPCR-Rev, 5′CACAGAAAGGACCCACAT3′; β-actin-qPCRFwd, 5′CGTGACATTAAGGAGAAGCTG3′; β-actin-qPCR-Rev, 5′CTAGA
| Deepsequencing
| Celllinecultureandtransfection
| RNAisolationanddetection
AGCATTTGCGGTGGAC3′; DANCR-qPCR-Fwd, 5′GCGCCACTATGTA
GCGGGTT3′; DANCR-qPCR-Rev, 5′TCAATGGCTTGTGCCTGTAGTT3′.
| MTTassay
HeLa and C33A cells were seeded into 96-well plates at 4500 cells per well 1 day prior to transfection as indicated. Cell viability at 48 and 72 hours post-transfection was determined by MTT assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan).
Absorbance values at 570 nm were measured using the Quant Microplate Spectrophotometer (BioTek, Winooski, VT, USA).
| Colonyformationassay
For the colony formation ability assay, HeLa and C33A cells were counted at 24 hours post-transfection and seeded into 24-well plates at 300 cells/well. Culture medium was replaced every 3 days.
After ~2 weeks, cells were washed with PBS. Subsequently, colonies were fixed with 4% paraformaldehyde at room temperature for 30 minutes and stained with 1% crystal violet at room temperature for 20 minutes. Number of colonies was counted under an inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany).
| Transwellmigrationandinvasionassay
HeLa and C33A cells transfected with the indicated plasmids were collected and suspended in serum-free medium. Subsequently, 
| Enhancedgreenfluorescentproteinreporter assayandLuciferasereporterassay
The hypothetical targets of miR-665 were predicted using TargetScan 
| Immunofluorescencestaining
HeLa cells transfected with specific plasmids were seeded in 24- 
| Invivotumorigenicityassay
Nude male BALB/c mice were used to determine tumorigenicity Tumor grafts were then excised and weighed.
| Westernblotanalysis
HeLa cells were lysed using the Protein Extraction kit according to the 
| Statisticalanalysis
All analyses were carried out using SPSS 19 and GraphPad Prism I, OncomiR database shows the level of miR-665 in cervical cancer patients and in control groups. J, Kaplan Meier plotter software shows that patients with low miR-665 level had a poor prognosis. Experiments were carried out three times, and data are presented as means ± SD. *P < .05; **P < .01; ***P < .001 used for comparisons of the other treatment groups with the corresponding controls. Pearson's correlation analysis was used to determine the r-value. Associations between miR-655 expression and clinicopathological characteristics were assessed using chi-squared test. Pearson's chi-squared test was used to count the Pearson value using SPSS19.0. Data from at least three independent experiments are presented as means ± SD, or medians with ranges. P < .05 was considered to indicate a statistically significant difference.
| RE SULTS
| MicroRNA-665wasdownregulatedincervical cancer
To investigate the potential involvement of miRNAs in CC, we carried out high-throughput microarray assay for miRNAs using three paired samples of tumor tissues and the adjacent tissues ( Figure 1A) . Figure 1D ).
Furthermore, KEGG pathway annotation showed that these target genes were significantly enriched in 20 canonical pathways, especially in metabolic pathways and tumorigenesis-related pathways ( Figure 1E ). RT-qPCR was used to verify the accuracy of the sequencing data, and the results showed that miR-665 was obviously downregulated compared with the other groups ( Figure 1F ).
Furthermore, we also detected the level of miR-665 in 30 paired tissues and the results showed that miR-665 was downregulated in CC tissues ( Figure 1G ), which was negatively correlated with tumor size, distant metastasis and advanced TNM stage (Table 1 ). In addition,
we analyzed the level of miR-665 in TCGA and the OncomiR database and found that the level of miR-665 was downregulated in CC patients ( Figure 1H,I ). Kaplan Meier plotter software showed that patients with a low miR-665 level had a poor prognosis ( Figure 1J ).
| MicroRNA-665inhibitedproliferation, migrationandinvasioninCCcells
In order to analyze the role of miR-665 on the progression of CC, the level of miR-665 was measured in CC cell lines. As shown in 
TA B L E 1 Association between miR-665 expression and clinicopathological characteristics in cervical cancer
F I G U R E 2 MicroRNA-665 (miR-665) functioned as a suppressor gene in cervical cancer (CC) cells. A, Expression levels of miR-665 in
End1/E6E7, H8, HeLa, C33A, SiHa and CasKi cells were examined by RT-qPCR assay. B, Efficiency of pri-miR-665 or ASO-miR-665 was identified by RT-qPCR assay. C, Effect of miR-665 on HeLa and C33A cellular viabilities was determined by MTT assay. D, Relative colony formation rates of HeLa and C33A cells with indicated treatment were determined by colony formation assay. E, Flow cytometric cell cycle analysis shows that miR-665 overexpression results in a significant increase in the cellular population in the G 0 /G 1 phase. F, Flow cytometric apoptosis shows that miR-665 overexpression significantly increased the apoptosis rate in HeLa and C33A cells. G,H, Transwell migration and invasion assays show that miR-665 suppressed cell migration and invasion ability. I, Western blot analysis of protein expression levels of E-cadherin, ICAM1 and vimentin following transfection with pri-miR-665 or ASO-miR-665 and the control groups in HeLa cells. J, miR-665 inhibited the drug resistance of HeLa and C33A cells to cisplatin. Experiments were carried out three times, and data are presented as means ± SD. *P < .05; **P < .01; ***P < .001; ns, not significant
| MicroRNA-665directlytargetedTGFBR1in CCcells
To investigate the mechanism of miR-665 affecting the biological behavior of CC, we predicted the target genes of miR-665 using miRDB and TargetScanHuman 7.2. To verify that miR-665 can directly target TGFBR1 3′UTR, we constructed EGFP reporter plasmids containing the 3′UTR or the 3′UTR-mut of TGFBR1
( Figure 3A) . In HeLa and C33A cells, relative EGFP activity was significantly reduced in both pri-miR-665 and wild-type (WT) 3′UTR
of the TGFBR1 cotransfected group and cotransfection with ASO-miR-665 and wild-type 3′UTR of TGFBR1 increased relative EGFP activity ( Figure 3B ). However, EGFP activity was not almost changed when HeLa and C33A cells were cotransfected with primiR-665 or ASO-miR-665 and mutational EGFP reporter plasmid ( Figure 3C ). To further confirm the regulation of TGFBR1 by miR-665, RT-qPCR and western blot assays were carried out and the results showed that pri-miR-665 markedly decreased the mRNA and protein levels of TGFBR1, and ASO-miR-665 increased the expression of TGFBR1 at the mRNA and protein levels ( Figure 3D ,E).
In addition, we detected the level of TGFBR1 using RT-qPCR assay and found that TGFBR1 mRNA level was markedly upregulated in tumor tissues compared to the adjacent tissues ( Figure 3F ).
Furthermore, using Pearson's correlation analysis, we also found that the mRNA level of TGFBR1 in tumor tissues was negatively correlated to the miR-665 level ( Figure 3G ). These data indicated that TGFBR1 is negatively regulated by miR-665 in CC cells, which is the novel target of miR-665.
| OverexpressionofTGFBR1rescuedthe phenotypescausedbymiR-665inCCcells
To determine the role of TGFBR1, we first detected the level of TGFBR1 in cervical cell lines and found that TGFBR1 was obviously F I G U R E 3 MicroRNA-665 (miR-665) directly targeted transforming growth factor beta receptor 1 (TGFBR1). A, Predicted miR-665 binding sites in TGFBR1 mRNA using TargetScan and miRDB are shown and the WT and the mutated 3′UTR of TGFBR1 mRNA are shown. B,C, enhanced green fluorescent protein intensity of HeLa and C33A cells expression in the WT or mutated 3′UTR of TGFBR1 was determined by spectrophotometry, and the value of the control group was set to 1. D, TGFBR1 mRNA expression levels in HeLa and C33A cells with indicated treatment were measured by RT-qPCR. E, TGFBR1 protein level in HeLa and C33A cells transfected with pri-miR-665 or ASO-miR-665 and respective controls were determined by western blot analysis. F, TGFBR1 mRNA levels in tumor tissues and adjacent tissues were detected by RT-qPCR assay. G, TGFBR1 mRNA expression level was negatively correlated with miR-665 level in tumor tissues. Experiments were carried out three times, and data are presented as means ± SD. *P < .05; **P < .01; ***P < .001; ns, not significant upregulated in CC cell lines compared with the control groups ( Figure 4A ). In addition, overexpression efficiency of TGFBR1 was confirmed by RT-qPCR and western blot assay ( Figure 4B,C) .
By MTT analysis and colony formation analysis, we showed that TGFBR1 promoted cell growth rate, presented as increased OD570 value and colony formation number, whereas miR-665 could reverse the increased growth effects induced by TGFBR1
( Figure 4D,E) . Flow cytometry analyses showed increased percent- only ( Figure 4G ). Transwell assay showed increased migration and invasion abilities upon TGFBR1 overexpression; however, when we carried out cotransfection with pri-miR-665 and pTGFBR1, all the effects we observed were neutralized by the addition of miR-665 ( Figure 4H,I ). Meanwhile, we carried out western blot to detect EMT markers to evaluate the effects of TGFBR1 in CC cells.
TGFBR1 overexpression decreased the expression of epithelial cell marker E-cadherin and increased the mesenchymal cell marker vimentin and ICAM1, indicating that TGFBR1 promoted EMT progression ( Figure 4J ).
| MicroRNA-665inactivatedtheERK/SMAD pathwaythroughTGFBR1
By western blot analyses, we showed that miR-665 inactivates the ERK/SMAD pathway as indicated by the suppressive expression of the phosphorylated form of ERK, SMAD2 and SMAD3, and p21, but with no changes for total expression of ERK, SMAD2 and SMAD3 ( Figure 5A ). However, combination treatments of miR-665
and TGFBR1 had no effects on this pathway. To detect the distribution of SMAD3, immunofluorescent assays were carried out in HeLa cells. Results showed that overexpression of miR-665 decreased the nuclear distribution of SMAD3 in HeLa cells. Cotransfection with pri-miR-665 and pTGFBR1 partly rescued the effects of miR-665 overexpression ( Figure 5B ).
| MicroRNA-665inhibitedtumorgrowth throughTGFBR1
To investigate the effects of miR-665 on the tumor growth in vivo, HeLa cells were transfected with pcDNA3 plus pcDNA3, pcDNA3
plus pri-miR-665, and pri-miR-665 plus pTGFBR1 s.c. injected into nude mice ( Figure 5C ). Our results showed that tumors from primiR-665 transfected HeLa cells grew more slowly than those from the control group or the pri-miR-665 and pTGFBR1 cotreatment group during the entire tumor growth period ( Figure 5D ). Average weights of tumors derived from pri-miR-665-transfected HeLa cells were significantly smaller than those of the control group or the primiR-665 and pTGFBR1 cotreatment group ( Figure 5E ).
| Longnoncoding-DANCRactsasamolecular spongeformiR-665inCCcells
According to the RegRNA 2.0 database, we found that lnc-DANCR carries putative miR-665 targeting sites ( Figure 6A ). Next, we con- However, we did not observe a significant difference in TGFBR1 level after transfection with lnc-DANCR and pri-miR-665 ( Figure 6G,H) . We detected the level of DANCR in tissues and found that the level of DNACR in tumor tissues was upregulated compared with the adjacent normal tissues ( Figure 6I ). Furthermore, using Pearson's correlation analysis, we also found that the mRNA level of TGFBR1 in tumor tissues was positively correlated with the lnc-DANCR level ( Figure 6J ).
Finally, Kaplan Meier plotter software showed that patients with high TGFBR1 level had a poor prognosis ( Figure 6K ). Experiments were carried out three times, and data are presented as means ± SD. *P < .05; **P < .01; ***P < .001; ns, not significant through sponging miR-335-5p. 32 In present study, we showed that lnc-DANCR functions as a ceRNA of miR-665 to regulate CC progression. Hence, the previous study and our present results indicate that lnc-DNACR could be a target for the future prevention and therapeutics of cervical cancer.
| D ISCUSS I ON
MicroRNA-665 was downregulated in ovarian cancer, 33 pancreatic cancer, 34 hepatocellular carcinoma, 35 inflammatory bowel disease, 36 and so on. However, the role and mechanism of miR-665
in CC remains unknown. In the present study, using microarray sequencing, TCGA and the OncomiR database we found that miR- . D, Tumor growth rate was significantly decreased after treatment with pri-miR-665. E, miR-665 inhibited tumor weight. Experiments were carried out three times, and data are presented as means ± SD. *P < .05; **P < .01; ***P < .001; ns, not significant
It is well known that miRNAs may directly target the 3′UTR of mRNAs and lead to mRNA decay or translation suppression. 37 We found that miR-665 could directly target TGFBR1 in HeLa and C33A and DANCR WT or mutant construct. E, RT-qPCR was used to assess lnc-DANCR levels in HeLa and C33A cells in response to altered miR-665 expression. F, RT-qPCR shows the expression level of miR-665 when the expression of lnc-DANCR was enhanced or suppressed. G,H, lnc-DANCR promoted transforming growth factor beta receptor 1 (TGFBR1) mRNA and protein levels in HeLa and C33A cells by sponging miR-665. I, RT-qPCR assay shows the level of lnc-DANCR in patients and in control groups. J, TGFBR1 mRNA expression level was positively correlated with DANCR level in tumor tissues. K, Kaplan Meier plotter software shows that patients with high TGFBR1 level had a poor prognosis. Experiments were carried out three times, and data are presented as means ± SD. *P < .05; **P < .01; ***P < .001; ns, not significant of SMAD2 and SMAD3. 38, 39 TGFBR1 promoted cell proliferation, migration and invasion in lung cancer, 40 pancreatic cancer, 41 and glioblastoma. 42 In this study, we reported that TGFBR1 promoted cell proliferation, migration, invasion and the cell cycle and inhibit cell apoptosis in HeLa and C33A cells. Furthermore, TGFBR1 overexpression could attenuate the inhibitive role of miR-665 on the ERK/SMAD pathway in cervical cancer cells.
In conclusion, the present study showed that miR-665 was downregulated in cervical cancer, and overexpression of miR-665
could inhibit growth and metastasis of cervical cancer. Our study elucidated a novel pathway in lnc-DANCR-mediated miR-665 targeting TGFBR1 on growth and metastasis, which suggests new therapeutic targets, including the ERK/SMAD signaling pathway, in the prevention and treatment of cervical cancer.
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